FMC 3Q 2026 Earnings Call - FMC CORP

Explicit Guidance:

• FY 2026 Revenue: Updated to a range of $1.04 billion to $1.14 billion for Q4 2026 (flat to prior year at midpoint).
• FY 2026 Q4 EBITDA: Expected between $210 million and $230 million, representing a 22% decline versus prior year.
• FY 2026 Q4 EPS: Adjusted EPS expected between $0.56 and $0.70.
• FY 2026 Interest Expense: Full-year guidance set at $270 million to $280 million (approx. $35 million increase vs. prior year).
• FY 2026 D&A: Depreciation and amortization expected to remain between $160 million and $170 million.
• FY 2026 Effective Tax Rate: Adjusted earnings tax rate expected at 12% to 14% (midpoint 13%).
• FY 2026 Free Cash Flow: Updated outlook of negative $350 million to negative $150 million (includes $180 million in restructuring spending); free cash flow before restructuring expected between negative $170 million and positive $30 million.
• FY 2027 Adjusted EBITDA: Preliminary planning indicates a range of at least $650 million to as much as $730 million.
• FY 2028 Adjusted EBITDA: Preliminary planning indicates a range of approximately $760 million to $840 million.
• FY 2028 Net Debt: Projected end-of-year net debt of approximately $3.1 billion (assuming India sale and Delaware leaseback close in Q4 2026).

Business-Segment Outlook:

• North America Business Model Transition: Completed transition on October 1, 2026, shifting from a high gross price/high rebate model to a model where upfront price is closer to expected net price to reduce channel inventory volatility.
• Q4 2026 Volume Drivers: Expected growth driven by increased direct-to-grower sales in Brazil, growth of new products, and improved competitiveness of FMC pricing.
• Q4 2026 Price Dynamics: Anticipated high single-digit price decline, primarily driven by strategic pricing actions for products transitioning to the post-patent phase.
• 2027 Growth Drivers: New active ingredients expected to increase, led by Fluent (new registrations pending in six countries) and differentiation in Rina (Rinaxapir) formulations; potential derogations for Isoflex in Spain, France, and Belgium.
• 2028 Growth Acceleration: Expect greater contribution from new actives with Fluent expansion, key Isoflex registrations in Europe, Dodilex registrations in Brazil and Asia, and the first launch of Remisoxafen.
• Core Business vs. Growth Platform: 2027 core business expected to grow in the low single digits (volume and price net positive); Growth platform (new actives) expected to grow ~50%.
• Manufacturing Footprint: Sales at "peer" manufacturing moving to low-cost sites; negative impact on partner sales in 2027, but long-term benefit to core brand business via lower cost base.
• Cost Structure: 2027 benefits from reduced product returns/rework and partial year benefits from manufacturing changes; 2028 expected to see full year benefits from new manufacturing footprint.

Market and Competitive Outlook:

• Channel Inventory Constraints: Customers holding the lowest inventory values seen historically due to high financing costs and supply/demand uncertainty; actions taken to reduce inventory value to unblock replenishment.
• Pricing Environment: High single-digit price declines in Q4 2026; expected shift to net positive price/volume growth in 2027 and 2028.
• Raw Material Costs: Not expected to be a major cost driver in 2027/2028 due to significant decreases in costs of goods sold resulting from the cleanup of channel inventory (fewer returns/reworks).
• Market Share: Improved competitiveness expected to drive volume growth as products move more quickly through the channel to growers.

Macro / Industry Outlook:

• Demand Trends: Challenging market conditions in Q4 2026 including depressed grower margins and demand uncertainty in multiple regions.
• Weather Risks: Potential impact from El Niño creating demand uncertainty.
• FX Impact: Expect a minor FX tailwind on revenue and a modest FX headwind on EBITDA for the remainder of 2026; Brazilian Real (BRL) volatility factored into planning without specific headwinds identified for 2027.
• Interest Rates: Higher interest expense driven by recent financing activity, expected to remain a cost headwind.
• Regulatory/Geopolitical: Disruptions in the Middle East (Strait of Hormuz) not expected to dramatically impact variable cost inflation in the near term compared to the impact of inventory cleanup.

Strategic Initiatives:

• Commercial Actions (Inventory Price Adjustment): Executing adjustments on select high-priced products sold since 2023 in Brazil, Argentina, U.S., and Canada to move inventory downstream; expected to reduce future cash collections by approximately $175 million over 4-6 quarters via credit notes/pricing credits.
• Transaction Closings:
  • India Business Sale: Expected to close December 1, 2026 to partner Crystal Crop; proceeds anticipated around $260 million (including ~$115M collected YTD).
  • Delaware Site: Sale-leaseback of Delaware site expected to close by end of 2026.
• R&D Strategy: Commitment to maintain current R&D spending levels through 2027; future consideration of partnership models for single-molecule new active development to accelerate speed and reduce cost.
• Tessenderlo Investment: $403 million equity investment closed September 23, 2026; Luc Tac added to Board of Directors; Tessenderlo now owns ~20% of FMC.

Risks and Headwinds to Outlook:

• Commercial Action Implementation: 2027 EBITDA range ($650M-$730M) is broad and contingent on the speed at which commercial actions improve product flow through the channel.
• Cash Flow Volatility: 2026 Free Cash Flow guidance assumes flat customer prepayments to 2025 levels; any deviation could impact liquidity.
• Restructuring Spending: 2027 expected to see continued "meaningful" restructuring spending (lower than 2026's $180M) impacting cash flow.
• Execution Risk: Confidence in rebuilding relies on successful execution of the transition to the new pricing model and the realization of cost benefits from the new manufacturing footprint.
• Tax Rate Sensitivity: Full-year effective tax rate guidance (12-14%) is subject to reported losses in 2026.

Management Tone on the Future:

• Inflection Point: Management views 2027 as the beginning of a financial inflection, with 2028 expected to be a year of much stronger cash generation and growth.
• Confidence Level: High confidence that commercial actions are "absolutely vital" to returning to top-line growth; tone is pragmatic regarding the necessity of near-term pain for long-term health.
• Strategic Shift: Focus has shifted entirely to top-line growth post-restructuring; future infrastructure cost adjustments will only be considered if top-line growth does not materialize.
• Customer Reception: Initial feedback on commercial actions described as "very positive," reinforcing the view that constraints are being addressed.

Miscellaneous:

• Non-GAAP Measures: Discussion relies on adjusted EPS, adjusted EBITDA, free cash flow, organic revenue growth, and "sales" (excluding India).
• Balance Sheet Health: Net debt of ~$3.4B at Q3 2026; covenants comfortably maintained (Secured debt to covenant EBITDA 1.4x; Interest coverage 2.3x).
• Cash Management: Intention to largely self-finance the seasonal working capital build in the first half of 2027 to prioritize liquidity.